NCT Number: NCT04755764
The purpose of the research is to characterize the effect of labetalol, atenolol, and nifedipine on maternal hemodynamics early in pregnancy. Patients will be given medication based on their hemodynamics and asked to return for a repeat measurement.
Interested in participating?
Request Info18 year–45 year
Female
Observational
Huntington, West Virginia, 25701, United States
Location status: Recruiting
David Chaffin, MD
SUB_INVESTIGATOR
Jesse Cottrell, MD
CONTACT
Jesse Cottrell, MD
PRINCIPAL_INVESTIGATOR
Morgan Ruley, MS
CONTACT
When a patient presents to the Maternal Hypertension Center at Cabell Huntington Hospital, she will receive a non-invasive hemodynamic assessment via the NICaS system as per usual protocol. The NICaS system uses impedance cardiography which provides a reliable assessment of cardiovascular, respiratory, and fluid parameters. In typical practice, the vasodilator nifedipine is initiated for increased systemic vascular resistance and elevated cardiac output is treated with beta blockade (via either atenolol or labetalol). The medication to be given to each subject will be based on their hemodynamics. Specifically, nifedipine will be given for a mean arterial pressure >100 and a beta blocker will be given for a cardiac output >8 l/min. The patients will be asked to return in one week for repeat ICG measurement.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Beta blocker
Other names: Normodyne, Trandate
Beta blocker
Other names: Tenormin
Calcium channel blocker
Other names: Adalat CC, Afeditab CR, Nifediac CC, Nifedical XL, Procardia, Procardia XL
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Measured in mmHg
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Measured in mmHg
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Measured in mmHg
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Measured in beats per minute
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Measured in liters per minute
Time frame: Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.
Measured by dynes · sec/cm^-5
Contact information is provided by the study sponsor or research team.
Jesse Cottrell, MD
CONTACT
Morgan Ruley, MS
CONTACT
Marshall University
Other
The Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by Impedance Cardiography in Early Pregnancy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07109739
Brachial Artery Flow-mediated Dilation, Cardiovascular Diseases
Minneapolis, Minnesota, United States
View Trial DetailsNCT05086523
Cardiovascular Diseases, Essential Hypertension
Prague, Czechia
View Trial DetailsNCT03712033
Blood Pressure, High, Brain Diseases
Vancouver, British Columbia, Canada
View Trial DetailsNCT01281306
Cardiovascular Diseases, Essential Hypertension
Clearwater, Florida, United States
View Trial Details